Valeant Pharmaceuticals International (VRX) Reaches New 1-Year High at $29.40

Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$29.40 and last traded at C$27.24, with a volume of 1404754 shares traded. The stock had previously closed at C$26.20.

Several research analysts have issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and set a C$23.00 price target on shares of Valeant Pharmaceuticals International in a report on Wednesday, November 8th. TD Securities upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price target for the company in a report on Wednesday, November 8th.

The firm has a market cap of $10,060.00, a PE ratio of 5.58 and a beta of -0.67.

In related news, Director Schutter Richard Urbain De acquired 10,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Friday, November 17th. The stock was bought at an average price of C$14.33 per share, with a total value of C$143,300.00.

WARNING: This piece was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/03/valeant-pharmaceuticals-international-vrx-reaches-new-1-year-high-at-29-40.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply